Please assess the completion status of the following clinical trial:

Trial Title: TicAgrelor Versus CLOpidogrel in Stabilized Patients With Acute Myocardial Infarction: TALOS-AMI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subject should meet all of the following criteria.~1. Age \>= 18 years~2. Patients with AMI (STEMI or NSTEMI) who are administered aspirin and ticagrelor for 30 days after successful PCI with newer-generation drug eluting stents (DES)~   \*Definition of AMI follows the 3rd Universal Definition of MI.~3. Female patients with childbearing potential who agree to mandatory pregnancy test and have committed to using adequate contraception~4. Subjects who agree to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate IRB of the respective institution~Exclusion Criteria:~Subject should be excluded if they apply to any of the following criteria.~1. Cardiogenic shock~2. Active internal bleeding, bleeding diathesis, or coagulopathy~3. Gastrointestinal bleeding or genitourinary bleeding, hemoptysis, or vitreous hemorrhage within 2 months~4. Major surgery within 6 weeks~5. History of intracranial bleeding, intracranial neoplasm, intracranial arteriovenous malformation, or intracranial aneurysm~6. Anemia (hemoglobin \< 10 g/dL) or platelet count of less than 100,000/mm3 at the time of screening~7. Concomitant treatment with oral anticoagulant agent (vitamin-K antagonists or novel oral anticoagulants such as dabigatran, rivaroxaban, apixaban, or edoxaban)~8. Daily treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 inhibitors~9. Malignancy or life expectancy of less than one year~10. Moderate or severe hepatic dysfunction (Child Pugh B or C)~11. Symptomatic patients with sinus bradycardia (sick sinus syndrome) or atrioventricular (AV) block (AV block grade II or III, bradycardia-induced syncope; except for patients implanted with permanent pacemaker)~12. Symptomatic patients with chronic obstructive pulmonary disease (Medical research council grade \>=3)~13. Intolerance of or allergy to aspirin, ticagrelor or clopidogrel~14. Subjects who are under renal replacement therapy due to end-stage renal disease or who have history of kidney transplantation~15. Galactose intolerance, lactase insufficiency or glucose-galactose malabsorption~16. Subjects who are actively participating in another clinical trial with 3 months of randomization (except for observational study)~17. Pregnant and/or lactating women~18. Subjects considered unsuitable for this study by the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aspirin+Ticagrelor (Type: ACTIVE_COMPARATOR): A Group treated with Aspirin+Ticagrelor
- Aspirin+Clopidogrel (Type: EXPERIMENTAL): A Group treated with Aspirin+Clopidogrel

Based on this trial design, predict the completion outcome and termination type (if applicable).